X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA ASTRAZENECA PHARMA PLETHICO PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x -1.1 155.7 - View Chart
P/BV x 0.0 24.2 0.1% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PLETHICO PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
ASTRAZENECA PHARMA
Mar-14
PLETHICO PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3951,285 30.7%   
Low Rs31634 4.9%   
Sales per share (Unadj.) Rs604.4189.6 318.8%  
Earnings per share (Unadj.) Rs32.5-0.2 -15,952.3%  
Cash flow per share (Unadj.) Rs51.33.8 1,335.1%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs473.668.6 689.9%  
Shares outstanding (eoy) m34.0825.00 136.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.45.1 7.0%   
Avg P/E ratio x6.6-4,712.7 -0.1%  
P/CF ratio (eoy) x4.2249.6 1.7%  
Price / Book Value ratio x0.514.0 3.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,26223,988 30.3%   
No. of employees `000NA1.6 0.0%   
Total wages/salary Rs m1,5961,605 99.5%   
Avg. sales/employee Rs ThNM3,040.2-  
Avg. wages/employee Rs ThNM1,029.2-  
Avg. net profit/employee Rs ThNM-3.3-  
INCOME DATA
Net Sales Rs m20,5984,740 434.6%  
Other income Rs m38692 419.5%   
Total revenues Rs m20,9844,832 434.3%   
Gross profit Rs m2,818-130 -2,170.8%  
Depreciation Rs m642101 634.7%   
Interest Rs m1,5930-   
Profit before tax Rs m969-139 -697.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m-1385 -2,718.7%   
Profit after tax Rs m1,107-5 -21,746.2%  
Gross profit margin %13.7-2.7 -499.5%  
Effective tax rate %-14.3-3.7 389.9%   
Net profit margin %5.4-0.1 -5,003.9%  
BALANCE SHEET DATA
Current assets Rs m18,8772,726 692.4%   
Current liabilities Rs m11,8962,435 488.6%   
Net working cap to sales %33.96.1 551.2%  
Current ratio x1.61.1 141.7%  
Inventory Days Days3674 48.7%  
Debtors Days Days19841 485.3%  
Net fixed assets Rs m9,8611,035 952.4%   
Share capital Rs m34150 681.4%   
"Free" reserves Rs m12,331942 1,308.4%   
Net worth Rs m16,1391,716 940.5%   
Long term debt Rs m4,7060-   
Total assets Rs m33,1464,156 797.5%  
Interest coverage x1.6NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.61.1 54.5%   
Return on assets %8.1-0.1 -6,651.3%  
Return on equity %6.9-0.3 -2,312.2%  
Return on capital %12.30-  
Exports to sales %21.45.7 374.9%   
Imports to sales %15.26.5 235.6%   
Exports (fob) Rs m4,402270 1,629.3%   
Imports (cif) Rs m3,136306 1,023.8%   
Fx inflow Rs m4,402375 1,175.2%   
Fx outflow Rs m3,184470 677.2%   
Net fx Rs m1,219-96 -1,275.2%   
CASH FLOW
From Operations Rs m2,437-8 -30,091.4%  
From Investments Rs m-6,265-146 4,299.7%  
From Financial Activity Rs m2,490862 288.8%  
Net Cashflow Rs m-1,337709 -188.7%  

Share Holding

Indian Promoters % 82.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.3 0.3 1,433.3%  
FIIs % 5.5 15.7 35.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 9.1 82.4%  
Shareholders   10,665 12,856 83.0%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 212.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 32 m (down 212.1% YoY). Sales on the other hand came in at Rs 2 bn (up 35.1% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS